{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:09:52Z","timestamp":1791684592640,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH1R21AR070540-01"],"award-info":[{"award-number":["NIH1R21AR070540-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01\u00a0AR075097"],"award-info":[{"award-number":["K01\u00a0AR075097"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV belimumab 10\u2009mg\/kg or placebo randomization and a 24-week open-label extension. Clinical responses were measured by the definition of improvement (DOI) and total improvement score (TIS). Flow cytometry analyses were performed on available samples before randomization, at 24 and 60\u201364\u2009weeks. Descriptive statistics, t-test, Fisher\u2019s exact test and analysis of variance tests were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 17 patients were randomized, 15 received five or more doses of belimumab or placebo and were included in the intention-to-treat analysis. More belimumab patients vs placebo attained a TIS \u226540 [55.5% vs 33.3%; P\u2009=\u2009non-significant (NS)] and achieved the DOI (33.3% vs 16.7%; P\u2009=\u2009NS) at weeks 40 and 64; the mean TIS was similar among groups. Two patients achieved major responses (TIS\u2009=\u200972.5) after week 40 in the belimumab arm and none in the placebo arm. No improvement in the placebo arm after switching to the open-label phase was observed. There was no steroid-sparing effect. No new safety signals were detected. Although total B cells were not reduced, belimumab induced na\u00efve B cell depletion while enhancing the number and frequency memory B cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study did not meet the primary endpoint and no statistically significant differences were observed in clinical responses between arms. More patients achieved sustained TIS \u226540 and reached the DOI. Most patients who received belimumab for &amp;gt;40\u2009weeks had clinical improvement. Phenotypic changes in B cell populations were not associated with clinical responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration number<\/jats:title>\n                    <jats:p>Clinicaltrials.gov (https:\/\/clinicaltrials.gov\/), NCT02347891<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead281","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T17:12:41Z","timestamp":1686849161000},"page":"742-750","source":"Crossref","is-referenced-by-count":33,"title":["Belimumab treatment of adult idiopathic inflammatory myopathy"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3625-1157","authenticated-orcid":false,"given":"Galina","family":"Marder","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Northwell Health, Donald and Barbara Zucker School of Medicine , Great Neck, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam","family":"Quach","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Northwell Health , Manhasset, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyal","family":"Chadha","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Northwell Health, Donald and Barbara Zucker School of Medicine , Great Neck, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeya","family":"Nandkumar","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Northwell Health, Donald and Barbara Zucker School of Medicine , Great Neck, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Tsang","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Northwell Health , Manhasset, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Levine","sequence":"additional","affiliation":[{"name":"Phoenix Neurological Associates , Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Schiopu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Michigan , Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Furie","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Northwell Health, Donald and Barbara Zucker School of Medicine , Great Neck, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Davidson","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Northwell Health, Donald and Barbara Zucker School of Medicine , Great Neck, NY, USA"},{"name":"Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Northwell Health , Manhasset, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6686-9441","authenticated-orcid":false,"given":"Sonali","family":"Narain","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Northwell Health, Donald and Barbara Zucker School of Medicine , Great Neck, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"2024030205495600300_kead281-B1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024030205495600300_kead281-B2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2024030205495600300_kead281-B3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"2024030205495600300_kead281-B4","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024030205495600300_kead281-B5","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205495600300_kead281-B6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/mus.21739","article-title":"Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles","volume":"42","author":"Salajegheh","year":"2010","journal-title":"Muscle Nerve"},{"key":"2024030205495600300_kead281-B7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/ard.2008.091405","article-title":"Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies","volume":"68","author":"Kry\u0161t\u016ffkov\u00e1","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2024030205495600300_kead281-B8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13075-018-1650-8","article-title":"Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis","volume":"20","author":"Kry\u0161t\u016ffkov\u00e1","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024030205495600300_kead281-B9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13075-014-0454-8","article-title":"Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52\/anti-Ro60 autoantibodies","volume":"16","author":"Kry\u0161t\u016ffkov\u00e1","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2024030205495600300_kead281-B10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jneuroim.2012.04.006","article-title":"The expression of BAFF in the muscles of patients with dermatomyositis","volume":"249","author":"Baek","year":"2012","journal-title":"J Neuroimmunol"},{"key":"2024030205495600300_kead281-B11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13023-020-01431-7","article-title":"Factors associated with refractory autoimmune necrotizing myopathy with anti-signal recognition particle antibodies","volume":"15","author":"Zhao","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2024030205495600300_kead281-B12","first-page":"S118","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)","volume":"63(Suppl 11)","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024030205495600300_kead281-B13","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2024030205495600300_kead281-B14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024030205495600300_kead281-B15","doi-asserted-by":"crossref","first-page":"e122525","DOI":"10.1172\/jci.insight.122525","article-title":"Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients","volume":"3","author":"Huang","year":"2018","journal-title":"JCI Insight"},{"key":"2024030205495600300_kead281-B16","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"2024030205495600300_kead281-B17","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2169\/internalmedicine.47.0967","article-title":"Flow cytometric analysis of lymphocyte subpopulations and TH1\/TH2 balance in patients with polymyositis and dermatomyositis","volume":"47","author":"Ishii","year":"2008","journal-title":"Intern Med"},{"key":"2024030205495600300_kead281-B18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jneuroim.2019.04.014","article-title":"Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome","volume":"332","author":"Dzangu\u00e9-Tchoupou","year":"2019","journal-title":"J Neuroimmunol"},{"key":"2024030205495600300_kead281-B19","doi-asserted-by":"crossref","first-page":"756018","DOI":"10.3389\/fimmu.2022.756018","article-title":"High-dimensional analysis reveals distinct endotypes in patients with idiopathic inflammatory myopathies","volume":"13","author":"Wilfong","year":"2022","journal-title":"Front Immunol"},{"key":"2024030205495600300_kead281-B20","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3389\/fimmu.2018.01372","article-title":"CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-\u03b1","volume":"9","author":"Piper","year":"2018","journal-title":"Front Immunol"},{"key":"2024030205495600300_kead281-B21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","article-title":"B cell alterations during BAFF inhibition with belimumab in SLE","volume":"40","author":"Ramsk\u00f6ld","year":"2019","journal-title":"EBioMedicine"},{"key":"2024030205495600300_kead281-B22","doi-asserted-by":"crossref","first-page":"e20202057","DOI":"10.1084\/jem.20202057","article-title":"The BAFFling persistence of memory B cells","volume":"218","author":"Brooks","year":"2021","journal-title":"J Exp Med"},{"key":"2024030205495600300_kead281-B23","doi-asserted-by":"crossref","first-page":"852162","DOI":"10.3389\/fmed.2022.852162","article-title":"Early changes in B and plasma cell subsets and traditional serological markers as predictors of SRI-4 response to therapy in systemic lupus erythematosus","volume":"9","author":"Parodis","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024030205495600300_kead281-B24","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024030205495600300_kead281-B25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024030205495600300_kead281-B26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4137\/CMAMD.S10272","article-title":"Phenotypes of peripheral blood lymphocytes and cytokine expression in polymyositis and dermatomyositis before treatment and after clinical remission","volume":"5","author":"Shimojima","year":"2012","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"2024030205495600300_kead281-B27","doi-asserted-by":"crossref","first-page":"102372","DOI":"10.1016\/j.autrev.2019.102372","article-title":"Antimalarial agents diminish while methotrexate, azathioprine, and mycophenolic acid increase BAFF levels in systemic lupus erythematosus","volume":"18","author":"Hern\u00e1ndez-Breijo","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2024030205495600300_kead281-B28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"2024030205495600300_kead281-B29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cellimm.2012.05.009","article-title":"Decrease in circulating DNA, IL-10 and BAFF levels in newly diagnosed SLE patients after corticosteroid and chloroquine treatment","volume":"276","author":"Cepika","year":"2012","journal-title":"Cell Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead281\/50741850\/kead281.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/3\/742\/56818738\/kead281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/3\/742\/56818738\/kead281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:50:50Z","timestamp":1709340650000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/3\/742\/7199609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6,16]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead281","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,6,16]]}}}